Equities research analysts at Morgan Stanley assumed coverage on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage set an “equal weight” rating and a $155.00 price target on the specialty pharmaceutical company’s stock. Morgan Stanley’s price objective indicates a potential upside of 3.81% from the company’s previous close.

Several other analysts have also recently weighed in on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday, August 30th. Mizuho cut shares of Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $162.00 to $150.00 in a research note on Tuesday, July 4th. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, August 29th. Deutsche Bank AG reaffirmed a “buy” rating and set a $176.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, July 4th. Finally, Wells Fargo & Company reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, August 29th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eighteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $179.79.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded down 0.72% during trading on Thursday, reaching $149.31. The company’s stock had a trading volume of 257,862 shares. The company’s 50-day moving average price is $148.70 and its 200 day moving average price is $151.49. The stock has a market capitalization of $8.97 billion, a price-to-earnings ratio of 23.00 and a beta of 1.05. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by ($0.13). The firm had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. Jazz Pharmaceuticals PLC’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.67 earnings per share. Analysts anticipate that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Morgan Stanley Begins Coverage on Jazz Pharmaceuticals PLC (JAZZ)” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/10/05/morgan-stanley-begins-coverage-on-jazz-pharmaceuticals-plc-jazz.html.

In related news, Director Paul L. Berns sold 662 shares of the stock in a transaction that occurred on Friday, August 11th. The shares were sold at an average price of $142.37, for a total value of $94,248.94. Following the transaction, the director now directly owns 6,599 shares in the company, valued at $939,499.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total transaction of $153,520.00. The disclosure for this sale can be found here. Insiders sold 9,297 shares of company stock worth $1,429,417 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in JAZZ. BlackRock Inc. lifted its holdings in Jazz Pharmaceuticals PLC by 3,163.9% in the first quarter. BlackRock Inc. now owns 3,215,159 shares of the specialty pharmaceutical company’s stock valued at $466,615,000 after buying an additional 3,116,652 shares during the period. Janus Henderson Group PLC lifted its holdings in Jazz Pharmaceuticals PLC by 11,990.7% in the second quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after buying an additional 866,691 shares during the period. FMR LLC lifted its holdings in Jazz Pharmaceuticals PLC by 11.4% in the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after buying an additional 849,348 shares during the period. Janus Capital Management LLC lifted its holdings in Jazz Pharmaceuticals PLC by 46.8% in the first quarter. Janus Capital Management LLC now owns 1,470,245 shares of the specialty pharmaceutical company’s stock valued at $213,367,000 after buying an additional 468,940 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Jazz Pharmaceuticals PLC by 41.2% in the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after buying an additional 410,031 shares during the period. Institutional investors and hedge funds own 88.34% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.